Introduction {#s1}
============

Nasopharyngeal carcinoma (NPC) originates from the nasopharynx epithelium. NPC is rare compared with other types of cancer; moreover, its geographical distribution presents a unique pattern ([@B1]): it is a highly common type of head and neck cancer in the eastern and southeastern parts of Asia. NPC tends to metastasize to distant sites in the head and neck, and about 70% of the patients with NPC present with stage III or IV disease at the time of initial diagnosis ([@B2]). Radiotherapy (RT) is primarily used to treat NPC; however, concurrent chemoradiotherapy (CCRT) is recommended as the standard treatment for locoregionally advanced NPC ([@B3]). Although the 5-year survival rate of patients with NPC is \~60--70%, NPC management remains challenging because of locoregional failure, recurrence, and distant metastasis after primary treatment ([@B4]). Currently, several prognostic parameters are used for NPC management, including age and sex ([@B5]). However, these parameters lack sensitivity or specificity in some patients with NPC, and are, therefore, insufficient for predicting survival outcomes. Thus, the identification of novel and efficient prognostic markers is highly important in NPC treatment.

Programmed cell death ligand-1 (PD-L1), also known as B7-H1 or CD274, was cloned in 1999 ([@B6]). PD-L1 belongs to the B7/CD28 co-stimulator superfamily and is highly expressed in tumor-associated antigen-presenting cells (APCs), dendritic cells ([@B7]), macrophages ([@B8]), T cells ([@B8]), and various types of cancer cells ([@B9], [@B10]). PD-L1 along with programmed cell death 1 (PD-1; CD279), which is an inhibitory receptor expressed by tumor-infiltrating lymphocytes, can induce T cells apoptosis and inhibit the proliferation of immune cells ([@B11]): PD-1 and PD-L1 constitute the immune checkpoint that promotes tumor immune evasion ([@B12]). Using immunohistochemistry (IHC), PD-L1 overexpression was shown to be associated with a poor prognosis across multiple tumor types ([@B10], [@B13]), including non-small cell lung cancer ([@B14]), hepatocellular carcinoma ([@B15]), colorectal cancer ([@B16]), and renal cell carcinoma ([@B17]). Several studies also demonstrated the relationship between PD-L1 expression and prognosis of patients with NPC; however, results were controversial ([@B18]--[@B23]). Therefore, we conducted a meta-analysis to assess the impact of PD-L1 on the prognosis of patients with NPC.

Materials and Methods {#s2}
=====================

Literature Search
-----------------

Eligible studies were identified by searching PubMed, Embase, Web of Science, and Cochrane Library up to April 2019. The following search terms were used: "Programmed Cell Death Ligand 1" or "Programmed Death Ligand 1" or "PDL1" or "B7-H1" or "CD274" or "Programmed Cell Death 1" or "Programmed Death 1" or "PD-1" or "CD279" and "nasopharyngeal carcinoma" or "nasopharyngeal cancer" or "NPC." References in the retrieved articles were also manually searched for additional studies.

Inclusion and Exclusion Criteria
--------------------------------

Eligible studies were identified according to the following inclusion criteria: (1) the NPC cases were pathologically confirmed; (2) PD-L1 expression was detected in NPC by using IHC; (3) studies provided the association between PD-L1 and survival outcomes and/or clinical characteristics; (4) studies provided the hazard ratio (HR) and 95% confidence interval (CI) for survival outcomes or sufficient information to calculate the HR and 95% CI in accordance with the methods by Parmar ([@B24]) and Tierney ([@B25]); (5) for studies ([@B22], [@B26], [@B27]) detected the expression of PD-L1 in both tumor cells (TCs) and immune cells (ICs), we only extracted the data of PD-L1 expression on TCs for analysis; and (6) original articles were published in English. The following were the exclusion criteria: (1) meeting abstracts, case reports, reviews, or letters; (2) duplicate studies; and (3) non-human studies.

Data Extraction and Quality Assessment
--------------------------------------

Two authors extracted relevant data independently, and disagreements were settled by discussion. The following data were extracted: the name of the first author; the year of publication; country/region; sample size; age; tumor stage; treatment modality; study design; study duration; and HR and 95% CI related to PD-L1 expression. The quality of eligible studies was evaluated according to the Newcastle-Ottawa Scale (NOS) ([@B28]). The scale includes three categories: selection, comparability, and outcome assessment. The top score is 9 points, and studies with a score \>6 are regarded as high-quality studies.

Statistical Analysis
--------------------

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines ([@B29]). Pooled HR and 95% CI were determined to assess the relationship between the PD-L1 and various survival outcomes. The pooled odds ratio (OR) and 95% CI were determined to study the correlation between PD-L1 and clinicopathological features. Statistical heterogeneity among all studies was assessed using the *I*^2^ and Chi-squared test. Heterogeneity was considered statistically significant when the *I*^2^ \> 50% or *P* \< 0.10. A random-effects model was used when significant heterogeneity was present; alternatively, a fixed-effects model was used. Sensitivity analysis and subgroup analysis were adopted to assess the heterogeneity and stability of the results. Begg\'s funnel plot was used to assess any publication bias ([@B30]). All statistical analyses were conducted with Stata version 12.0 statistical software (Stata Corporation, College Station, TX, US). A *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Literature Search
-----------------

A total of 166 related studies were initially retrieved. As shown in [Figure 1](#F1){ref-type="fig"}, following the exclusion of 64 duplicate studies, 102 studies were screened. Eighty-six studies were excluded after title and/or abstract screening for the following reasons: not based on NPC (*n* = 35), reviews (*n* = 21), non-human studies (*n* = 17), and not related to PD-L1 (*n* = 13). Thereafter, the full text of 16 studies was assessed; five studies were excluded because of insufficient data (*n* = 2), duplicate studies from the same research group (*n* = 2), and no use of IHC (*n* = 1). Finally, 11 studies were included in this meta-analysis ([@B18]--[@B23], [@B26], [@B27], [@B31]--[@B33]).

![Flowchart of study selection.](fonc-09-01111-g0001){#F1}

Study Characteristics
---------------------

Baseline characteristics of the eligible studies are summarized in [Table 1](#T1){ref-type="table"}. The studies were published from 2016 to 2019 and were all conducted in Asia. Six studies were conducted in China ([@B20]--[@B23], [@B32], [@B33]), and one each were in Hong Kong ([@B18]), Philippines ([@B19]), Thailand ([@B31]), Taiwan ([@B26]), and Japan ([@B27]), respectively. Eight studies detected the expression of PD-L1 in TCs ([@B18]--[@B23], [@B31]--[@B33]) and 3 studies detected PD-L1 expression in both TCs and ICs ([@B22], [@B26], [@B27]). The data of PD-L1 expression of TCs were used for meta-analysis. Five studies recruited patients with both non-metastatic and metastatic NPC ([@B19], [@B21], [@B26], [@B31], [@B33]), 4 studies recruited patients with non-metastatic NPC ([@B18], [@B23], [@B27], [@B32]), and 2 studies did not provide the information on metastatic status ([@B20], [@B22]). Nine studies included non-treated NPC patients ([@B18]--[@B20], [@B23], [@B26], [@B27], [@B31]--[@B33]), one study recruited recurrent patients ([@B21]), and one study included previously-treated patients ([@B22]). In addition, 6 studies recruited patients with non-keratinizing histology type (WHO II) ([@B19]--[@B21], [@B26], [@B31], [@B32]), 2 studies included patients with both keratinizing and non-keratinizing histology types ([@B27], [@B33]), and 3 studies did not provide relevant data ([@B18], [@B22], [@B23]). The sample size ranged from 56 to 209 and the total number of patients was 1,315. There was one prospective study ([@B23]) and the remaining 10 studies were retrospective. The NOS scores ranged from 6 to 9 and the mean was 7.36; this indicated that all included studies were of high quality.

###### 

Basic characteristics of eligible studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**                   **Country**\   **Sample**\   **Sex (M/F)**   **Age**         **Tumor stage**   **Study period**   **Treatment**\   **Detection method**   **Study**\      **NOS score**   **Cell type**   **Metastatic status**   **Disease type**     **Histology type**
                                   **/region**    **size**                                                                           **method**                              **design**                                                                                   
  -------------------------------- -------------- ------------- --------------- --------------- ----------------- ------------------ ---------------- ---------------------- --------------- --------------- --------------- ----------------------- -------------------- --------------------
  Lee et al. ([@B18])              Hong Kong      104           85/19           53 (27--80)     I--IV             2005--2009         CCRT             IHC                    Retrospective   7               TC              Non-metastatic          Non-treated          NA

  Chang et al. ([@B19])            Philippines    56            43/13           48.5 (19--71)   I--IV             2008--2011         CCRT             IHC                    Retrospective   8               TC              Mixed                   Non-treated          Non-keratinizing

  Li et al. ([@B20])               China          120           86/34           48 (17--69)     I--IV             2009--2012         CCRT, RT         IHC                    Retrospective   7               TC              NA                      Non-treated          Non-keratinizing

  Zhou et al. ([@B21])             China          132           106/26          46 (28--69)     II--III           2001--2013         CCRT, RT         IHC                    Retrospective   7               TC              Mixed                   Recurrent            Non-keratinizing

  Zhu et al. ([@B22])              China          209           150/59          52 (20--75)     I--IV             1991--2000         CCRT             IHC                    Retrospective   8               TC, IC          NA                      Previously-treated   NA

  Cao et al. ([@B23])              China          108           79/29           47 (16--68)     III--IV           2012--2014         CCRT             IHC                    Prospective     9               TC              Non-metastatic          Non-treated          NA

  Larbcharoensub et al. ([@B31])   Thailand       114           77/37           51.6            I--IV             2007--2012         CCRT, RT         IHC                    Retrospective   7               TC              Mixed                   Non-treated          Non-keratinizing

  Liu et al. ([@B26])              Taiwan         208           146/62          49 (20--84)     I--IV             NA                 CCRT             IHC                    Retrospective   8               TC, IC          Mixed                   Non-treated          Non-keratinizing

  Ono et al. ([@B27])              Japan          66            54/12           59.5 (13--85)   I--IV             2000--2015         CCRT             IHC                    Retrospective   7               TC, IC          Non-metastatic          Non-treated          Mixed

  Qu et al. ([@B32])               China          96            72/24           NA              I--IV             NA                 RT               IHC                    Retrospective   6               TC              Non-metastatic          Non-treated          Non-keratinizing

  Zhao et al. ([@B33])             China          102           66/46           49 (23--76)     I--IV             2017--2018         CCRT             IHC                    Retrospective   7               TC              Mixed                   Non-treated          Mixed
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*M, male; F, female; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; IHC, Immunohistochemical staining; NOS, Newcastle-Ottawa Scale; TC, tumor cell; IC, immune cell; NA, not available*.

Relationship Between PD-L1 Expression and Prognosis of NPC
----------------------------------------------------------

Nine studies ([@B18]--[@B23], [@B26], [@B27], [@B31]) with 1,117 patients reported the prognostic value of PD-L1 regarding overall survival (OS). The results revealed that PD-L1 overexpression was associated with significantly poorer OS compared with PD-L1-negative tumors (HR = 1.48, 95% CI = 1.00--2.18, *p* = 0.049; [Table 2](#T2){ref-type="table"} and [Figure 2A](#F2){ref-type="fig"}). The pooled HR and 95% CI from six studies ([@B18], [@B20], [@B22], [@B23], [@B26], [@B27]) indicated that PD-L1 overexpression was not correlated with poor disease-free survival (DFS; HR = 1.51, 95% CI = 0.85--2.69, *p* = 0.162; [Table 2](#T2){ref-type="table"} and [Figure 2B](#F2){ref-type="fig"}). As shown in [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}, the pooled data also demonstrated that PD-L1 overexpression was not correlated with distant metastasis-free survival (DMFS; HR = 1.75, 95% CI = 0.64--4.79, *p* = 0.277) or local recurrence-free survival (LRFS; HR = 0.67, 95% CI = 0.06--8.16, *p* = 0.756).

###### 

Meta-analysis of association between PD-L1 and OS, DFS, DMFS, LRFS in nasopharyngeal carcinoma.

  -----------------------------------------------------------------------------------------------------------------------------
  **Subgroup**         **No. of**\   **No. of**\    **HR (95%CI)**      ***p***   **Heterogeneity**   **Effects model**   
                       **studies**   **patients**                                                                         
  -------------------- ------------- -------------- ------------------- --------- ------------------- ------------------- -----
  OS                   9             1,117          1.48 (1--2.18)      0.049     51.8                0.035               REM

  **Tumor stage**                                                                                                         

  I--IV                7             877            1.37 (0.84--2.24)   0.204     59                  0.023               REM

  II--III              1             132            1.89 (1.13--3.17)   0.016     --                  --                  --

  III--IV              1             108            2.23 (0.52--9.60)   0.049     --                  --                  --

  **Disease type**                                                                                                        

  Non-treated          7             776            1.52 (0.86--2.70)   0.148     59.1                0.023               REM

  Recurrent/\          2             341            1.47 (1.01--2.14)   0.044     47                  0.17                FEM
  previously-treated                                                                                                      

  **Study design**                                                                                                        

  Retrospective        8             1,009          1.44 (0.96--2.18)   0.081     56.8                0.023               REM

  Prospective          1             108            2.23 (0.52--9.60)   0.283     --                  --                  --

  DFS                  6             815            1.51 (0.85--2.69)   0.162     65.1                0.014               REM

  **Tumor stage**                                                                                                         

  I--IV                5             707            1.45 (0.74--2.86)   0.283     71.1                0.008               REM

  III--IV              1             108            1.97 (0.75--5.17)   0.172     --                  --                  --

  **Treatment**                                                                                                           

  Non-treated          5             606            1.70 (0.80--3.59)   0.165     68.6                0.013               REM

  Recurrent/\          1             209            1.04 (0.58--1.84)   0.902     --                  --                  --
  previously-treated                                                                                                      

  DMFS                 3             408            1.75 (0.64--4.79)   0.277     64.7                0.059               REM

  LRFS                 2             312            0.67 (0.06--8.16)   0.756     83.1                0.015               REM
  -----------------------------------------------------------------------------------------------------------------------------

*OS, overall survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; LRFS, local recurrence-free survival; FEM, fixed-effects model; REM, random-effects model*.

![Forest plot diagrams of hazard ratios for correlations between PD-L1 expression and **(A)** OS, **(B)** DFS, **(C)** DMFS, and **(D)** LRFS.](fonc-09-01111-g0002){#F2}

The Association of PD-L1 Expression With Clinicopathological Features
---------------------------------------------------------------------

To explore the correlation between PD-L1 expression and clinicopathological characteristics of NPC, the pooled OR and 95% CI were determined. As shown in [Table 3](#T3){ref-type="table"}, the pooled data indicated that PD-L1 overexpression was not associated with T stage (OR = 1.25, 95% CI = 0.85--1.84, *p* = 0.261; random-effects model), N stage (OR = 0.98, 95% CI = 0.76--1.27, *p* = 0.885; fixed-effects model), M stage (OR = 0.79, 95% CI = 0.47--1.33, *p* = 0.374; fixed-effects model), overall stage (OR = 1.31, 95% CI = 0.95--1.81, *p* = 0.1; fixed-effects model), sex (OR = 1.20, 95% CI = 0.78--1.33, *p* = 0.871; fixed-effects model), age (OR = 1.06, 95% CI = 0.77--1.46, *p* = 0.726; fixed-effects model), smoking (OR = 0.81, 95% CI = 0.61--1.09, *p* = 0.162; fixed-effects model), or alcohol intake (OR = 0.72, 95% CI = 0.43--1.19, *p* = 0.196; fixed-effects model).

###### 

The association between PD-L1 and clinical factors.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Clinical factors**                **No. of**\   **No. of**\    **HR (95%CI)**      ***p***   **Heterogeneity**   **Effects model**   **Begg\'s *p***   
                                      **studies**   **patients**                                                                                           
  ----------------------------------- ------------- -------------- ------------------- --------- ------------------- ------------------- ----------------- -------
  T stage (T3--T4 vs. T1--T2)         11            1,315          1.25 (0.85--1.84)   0.261     51.6                0.024               REM               0.938

  Sex (male vs. female)               11            1,315          1.20 (0.78--1.33)   0.871     0                   0.813               FEM               0.862

  N stage (N2--N3 vs. N1--N0)         11            1,315          0.98 (0.76--1.27)   0.885     0                   0.529               FEM               0.276

  Smoking (yes vs. no)                8             906            0.81 (0.61--1.09)   0.162     0                   0.45                FEM               0.536

  Overall stage (III--IV vs. I--II)   7             913            1.31 (0.95--1.81)   0.1       0                   0.782               FEM               0.881

  M stage (M1 vs. M0)                 6             785            0.79 (0.47--1.33)   0.374     0                   0.78                FEM               0.260

  Age (y) (\>45 vs. ≤45)              6             767            1.06 (0.77--1.46)   0.726     45.4                0.103               FEM               0.851

  Alcohol use (yes vs. no)            3             330            0.72 (0.43--1.19)   0.196     0                   0.683               FEM               0.602
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

*FEM, fixed-effects model; REM, random-effects model*.

Subgroup Analysis and Sensitivity Analysis
------------------------------------------

Because several baseline characteristics varied among included studies, which may cause heterogeneity in meta-analysis. Therefore, subgroup analysis was conducted for OS and DFS. As shown in [Table 2](#T2){ref-type="table"}, PD-L1 expression was associated with poor OS in patients with stage II-III (*n* = 1, *p* = 0.016), stage III-IV (*n* = 1, *p* = 0.049), and recurrent/ previously-treated patients (*n* = 2, *p* = 0.044). However, PD-L1 was not significantly correlated to OS in both retrospective and prospective studies. Subgroup analysis also showed that PD-L1 remained a non-significant prognostic marker for DFS irrespective of tumor stage and disease type. Subgroup analysis was not performed for DMFS and LRFS because of the limited number of studies and uniformity among these studies. Sensitivity analysis by omitting one study in each turn was conducted to test the credibility of the prognostic value of PD-L1. As shown in [Figure 3A](#F3){ref-type="fig"}, the results for OS were significantly altered when Li\' s study ([@B20]) was excluded. Therefore, we re-analyzed the prognostic value of PD-L1 for OS after exclusion of Li\'s study ([@B20]), the results were HR = 1.33, 95% CI = 1.04--1.70, *p* = 0.022; *I*^2^ = 0, *P* = 0.513 ([Figure S1](#SM1){ref-type="supplementary-material"}). The heterogeneity in the analysis of PD-L1 and OS was significantly reduced after deletion of Li\'s study (*I*^2^ = 0, *P* = 0.513). No other individual study influenced the results for DFS, DMFS, and LRFS ([Figure 3](#F3){ref-type="fig"}). The results of prognosis of PD-L1 and OS were more significant after sensitivity analysis, which suggested that PD-L1 could be a prognostic factor for OS in NPC patients.

![Sensitivity analysis for **(A)** OS, **(B)** DFS, **(C)** DMFS, and **(D)** LRFS.](fonc-09-01111-g0003){#F3}

Publication Bias
----------------

Begg\'s tests showed that there was no publication bias in the eligible studies involving PD-L1 and OS (*p* = 0.602), DFS (*p* = 0.452), DMFS (*p* = 1), and LRFS (*p* = 0.317) ([Figure 4](#F4){ref-type="fig"}). In addition, the funnel plots showed no publication bias for clinicopathological factors ([Table 3](#T3){ref-type="table"}).

![Funnel plots for publication bias of **(A)** OS, **(B)** DFS, **(C)** DMFS, and **(D)** LRFS.](fonc-09-01111-g0004){#F4}

Discussion {#s4}
==========

Many studies demonstrated that PD-L1 plays an important role in tumor immune evasion ([@B34], [@B35]). The upregulation of PD-L1 inhibits T cell function and triggers immune evasion in cancer ([@B36]). In the tumor microenvironment, tumor-associated PD-L1 increases the apoptosis of T cells and leads to the growth of immunogenic tumors ([@B36]). PD-L1 is mainly expressed on the surface of tumor cells and tumor-associated APCs in various types of cancer including pancreatic cancer ([@B37]), ovarian cancer ([@B38]), thymoma ([@B39]), and colorectal cancer ([@B40]). PD-L1 and its receptor PD-1 constitute the PD-1/PD-L1 immune checkpoint signaling pathway ([@B41]). Checkpoint inhibition targets regulatory pathways in T cells to promote anti-tumor immune responses ([@B12], [@B42]). A recent phase II clinical trial including 44 patients revealed a promising activity of the PD-L1 antibody in NPC and a favorable 1-year OS rate ([@B43]). This study also suggested an association of PD-L1 expression with a higher response rate in patients with NPC ([@B43]).

To the best of our knowledge, this is the first meta-analysis to investigate the prognostic and clinicopathologic significance of PD-L1 expression in NPC. Survival data of 1,315 patients from 11 eligible studies were systematically analyzed. We found that PD-L1 overexpression was a significant prognostic factor for poor OS, whereas PD-L1 expression did not predict worse DFS, DMFS, or LRFS. Furthermore, PD-L1 expression was independent of T stage, N stage, M stage, overall stage, sex, smoking, age, or alcohol intake. Overall, this meta-analysis highlighted the potential of PD-L1 as a prognostic biomarker for poor OS in patients with NPC.

Previous meta-analyses exploring the prognostic value of PD-L1 in solid malignant tumors also indicated the unfavorable impact of PD-L1 on survival outcomes ([@B10], [@B44], [@B45]). A meta-analysis involving 13 studies showed that a high PD-L1 expression could predict a shorter OS (HR = 1.57, 95% CI = 1.09--2.27, *P* \< 0.00001) and poorer DFS (HR = 2.07, 95% CI = 1.20--3.58, *P* = 0.009) in hepatocellular carcinoma ([@B15]). Another study also demonstrated a significant association of PD-L1 expression with a poor biochemical recurrence-free survival (BCR-FS) (HR = 1.78; 95% CI = 1.39 to 2.27; *p* \< 0.00001) in prostate cancer ([@B46]). Wang et al. showed an association of PD-L1 expression with a poor OS in RCC ([@B47]). In addition, PD-L1 expression was found to be significantly associated with tumor stage, regional lymph node involvement, distant metastases, nuclear grade, and histologic tumor necrosis in RCC ([@B47]). The current meta-analysis showed the positive correlation of PD-L1 with OS, but not with DFS, DMFS, or LRFS. This may due to the limited sample size and the relatively short follow-up duration. Furthermore, we did not detect any association of PD-L1 with clinical factors in NPC. This requires further verification in future prospective studies.

There are several limitations in this study. First, all the eligible studies were conducted in Asia, which may reflect the high incidence of NPC in Asia. However, the results of this meta-analysis might be applied to patients in Asia. Second, although we selected eligible studies using uniform criteria, inter-study heterogeneity still exists in this meta-analysis. Therefore, subgroup analysis was performed to detect the source of heterogeneity. Third, the majority of the eligible studies were retrospective in design, which may compromise the validity of this study.

Conclusions {#s5}
===========

In summary, this meta-analysis showed that PD-L1 overexpression in NPC was associated with poor OS and may be useful as a novel prognostic factor. Nevertheless, because of the aforementioned limitations, well-designed, large-scale, prospective clinical trials are required to verify the findings of this meta-analysis.
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Meta-analysis of PD-L1 overexpression was associated with worse OS after deletion of Li\'s study.
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